Last reviewed · How we verify
BIOD-123
BIOD-123 is a rapid-acting insulin formulation designed to improve postprandial glucose control in diabetes patients.
BIOD-123 is a rapid-acting insulin formulation designed to improve postprandial glucose control in diabetes patients. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | BIOD-123 |
|---|---|
| Sponsor | Biodel |
| Drug class | Rapid-acting insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
BIOD-123 combines insulin lispro with proprietary excipients to accelerate insulin absorption and onset of action compared to standard rapid-acting insulins. This allows for faster glucose lowering after meals and potentially improved overall glycemic control with more physiologic insulin kinetics.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Lipodystrophy
Key clinical trials
- A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®) (PHASE2)
- Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIOD-123 CI brief — competitive landscape report
- BIOD-123 updates RSS · CI watch RSS
- Biodel portfolio CI